-
UK launch for Novo's new diabetes pill
pharmatimes
September 02, 2020
Novo Nordisk has launched in the UK the first 'protein in a pill' treatment for type II diabetes.
-
Mylan, Biocon Biologics Announce Launch of Semglee in U.S.
americanpharmaceuticalreview
September 01, 2020
Mylan and Biocon Biologics India announced the U.S. launch of Semglee™ (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with...
-
Diabetes drug, Dapagliflozin shows benefits in patients with CKD
expresspharma
September 01, 2020
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 per cent.
-
Biocon Biologics and Mylan launch Semglee (insulin glargine injection) in US
expresspharma
September 01, 2020
Mylan is offering Semglee at a wholesale acquisition cost (WAC) of $147.98 per package of five 3ml pens and $98.65 per 10ml vial.
-
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults
expresspharma
August 31, 2020
Boehringer Ingelheim announced the full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes.
-
Artificial pancreas for type 1 diabetes control given nod by FDA
europeanpharmaceuticalreview
August 28, 2020
The all-in-one, Control-IQ system controlled the blood glucose levels of children aged six and over more successfully than standard technologies in a clinical trials.
-
Precigen ActoBio Announces Positive Topline Results from Type 1 Diabetes Treatment Study
americanpharmaceuticalreview
August 13, 2020
Precigen ActoBio has met the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of early-onset type 1 diabetes (T1D).
-
Lupin gets tentative approval from US FDA for empagliflozin tablets
expresspharma
August 05, 2020
Empagliflozin tablets are used to treat type 2 diabetes mellitus as an adjunct to diet and exercise.
-
People at high risk of diabetes fast-tracked into prevention programme
pharmatimes
July 27, 2020
People at high risk of developing type II diabetes will be fast-tracked into the Healthier You NHS Diabetes Prevention programme, on the back of research indicating that people with the condition are at significantly higher risk of dying with COVID-19.
-
IQVIA and JDRF collaborate to improve understanding of Type 1 Diabetes using real world data
expresspharma
July 24, 2020
The collaboration will pave the way for development of a real world research platform to facilitate evidence generation in type 1 diabetes for multiple stakeholders.